Novo adds to Wegovy’s cardio strength with hospital admissions analysis

Kyle LaHucik

Senior Reporter

SAN ANTONIO — Novo Nordisk’s wildly popular anti-obesity drug Wegovy helped heart disease patients end up in the hospital less often and stay there for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo adds to Wegovy’s cardio strength with hospital admissions analysis

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Is there room for MASH drugs in a GLP-1 world?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

The election is Tuesday. What’s at stake for the pharma industry?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Novo adds to Wegovy’s cardio strength with hospital admissions analysis

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

The election is Tuesday. What’s at stake for the pharma industry?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks